➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Merck
Baxter
Harvard Business School
Mallinckrodt
Colorcon

Last Updated: February 27, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for LUM001

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug LUM001?

LUM001 is an investigational drug.

There have been 14 clinical trials for LUM001. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2019.

The most common disease conditions in clinical trials are Cholestasis, Alagille Syndrome, and Syndrome. The leading clinical trial sponsors are Shire, Mirum Pharmaceuticals, Inc., and Lumena Pharmaceuticals, Inc.

There are eight US patents protecting this investigational drug and one hundred and twenty-four international patents.

Recent Clinical Trials for LUM001
TitleSponsorPhase
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).Mirum Pharmaceuticals, Inc.Phase 2
Evaluation of Maralixibat in Biliary Atresia Response Post-KasaiMirum Pharmaceuticals, Inc.Phase 2
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat StudyMirum Pharmaceuticals, Inc.Phase 2

See all LUM001 clinical trials

Clinical Trial Summary for LUM001

Top disease conditions for LUM001
Top clinical trial sponsors for LUM001

See all LUM001 clinical trials

US Patents for LUM001

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LUM001   Start Trial Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake G.D. Searle and Company (Skokie, IL)   Start Trial
LUM001   Start Trial Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake G.D. Searle and Company (Skokie, IL)   Start Trial
LUM001   Start Trial Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake G.D. Searle and Company (Skokie, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Baxter
Harvard Business School
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.